John A. Jarcho, M.D., Julie R. Ingelfinger, M.D., Mary Beth Hamel, M.D., M.P.H., Ralph B. D’Agostino, Sr., Ph.D., and David P. Harrington, Ph.D. Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. The New England Journal of Medicine (June 2020). DOI: 10.1056/NEJMe2012924
https://www.nejm.org/doi/full/10.1056/NEJMe2012924?query=recirc_curatedRelated_article

University of California, Berkeley

- Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19 (Editorial)
- Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (article)
- Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 (article)
- Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (article)

The New England Journal of Medicine Papers Related to COVID-19 Patient Comorbidities

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19

Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med 2020; 382:e102 (June 2020) DOI: 10.1056/NEJMoa2007621
https://www.nejm.org/doi/full/10.1056/NEJMoa2007621

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19


Giuseppe Mancia, M.D., Federico Rea, Ph.D., Monica Ludergnani, M.Sc., Giovanni Apolone, M.D., and Giovanni Corrao, Ph.D. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382:2431-2440. DOI: 10.1056/NEJMoa2006923
https://www.nejm.org/doi/full/10.1056/NEJMoa2006923

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Reynolds et al., Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382:2441-2448. DOI: 10.1056/NEJMoa2008975
https://www.nejm.org/doi/full/10.1056/NEJMoa2008975

Learn Before

Related